These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 1497685)

  • 1. Steady state concentrations and diurnal fluctuations of carbamazepine in patients after different slow release formulations.
    Wolf P; May T; Tiska G; Schreiber G
    Arzneimittelforschung; 1992 Mar; 42(3):284-8. PubMed ID: 1497685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative evaluation of pharmacokinetics of conventional and slow-release carbamazepine formulation in newly treated patients of epilepsy: a random evaluation.
    Nag D; Garg RK; Agarwal A
    J Assoc Physicians India; 1998 Feb; 46(2):185-8. PubMed ID: 11273108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative bioavailability study of a conventional and two controlled release oral formulations of Tegretol (carbamazepine)--200 mg.
    Revankar SN; Bhatt AD; Desai ND; Bolar HV; Sane SP; Tipnis HP
    J Assoc Physicians India; 1999 Sep; 47(9):886-9. PubMed ID: 10778658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved CNS tolerability following conversion from immediate- to extended-release carbamazepine.
    Miller AD; Krauss GL; Hamzeh FM
    Acta Neurol Scand; 2004 Jun; 109(6):374-7. PubMed ID: 15147458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of carbamazepine Divitabs and a normal carbamazepine preparation in psychiatric and oligophrenic patients.
    Nijdam JR; Doorschot CH; van Bavel LP; Loonen AJ
    Pharmacopsychiatry; 1992 May; 25(3):145-9. PubMed ID: 1635933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breakthrough seizures with generic carbamazepine: a consequence of poorer bioavailability?
    Hartley R; Aleksandrowicz J; Ng PC; McLain B; Bowmer CJ; Forsythe WI
    Br J Clin Pract; 1990 Jul; 44(7):270-3. PubMed ID: 2206824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simulation of the effect of patient nonadherence on plasma concentrations of carbamazepine from twice-daily extended-release capsules.
    Garnett WR; McLean AM; Zhang Y; Clausen S; Tulloch SJ
    Curr Med Res Opin; 2003; 19(6):519-25. PubMed ID: 14594524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioavailability study of two carbamazepine containing sustained release formulations after multiple oral dose administration.
    Wangemann M; Retzow A; Evers G; Mazur D; Schug B; Blume H
    Arzneimittelforschung; 1998 Dec; 48(12):1131-7. PubMed ID: 9893926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative bioavailability of carbamazepine from two slow-release preparations.
    Reunanen M; Heinonen EH; Nyman L; Anttila M
    Epilepsy Res; 1992 Mar; 11(1):61-6. PubMed ID: 1563339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of care, outcomes, and direct health plan costs of antiepileptic therapy: a pharmacoeconomic analysis of the available carbamazepine formulations.
    Garnett WR; Gilbert TD; O'Connor P
    Clin Ther; 2005 Jul; 27(7):1092-103. PubMed ID: 16154489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetic modelling of carbamazepine in epileptic elderly patients: implications for dosage.
    Bondareva IB; Jelliffe RW; Gusev EI; Guekht AB; Melikyan EG; Belousov YB
    J Clin Pharm Ther; 2006 Jun; 31(3):211-21. PubMed ID: 16789986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the cognitive effects of tiagabine and carbamazepine as monotherapy in newly diagnosed adult patients with partial epilepsy: pooled analysis of two long-term, randomized, follow-up studies.
    Aikiä M; Jutila L; Salmenperä T; Mervaala E; Kälviäinen R
    Epilepsia; 2006 Jul; 47(7):1121-7. PubMed ID: 16886974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A practical study of the efficacy of a delayed-action preparation of carbamazepine (Tegretol CR 400) in the treatment of patients with partial epilepsy ].
    Vojvodić NM; Sokić DV; Janković SM; Lević Z
    Srp Arh Celok Lek; 2002; 130(1-2):19-26. PubMed ID: 12073283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of food on the bioavailability of a carbamazepine slow-release formulation.
    Retzow A; Schürer M; Schulz HU
    Int J Clin Pharmacol Ther; 1997 Dec; 35(12):557-60. PubMed ID: 9455713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formulation and in vitro/in vivo investigation of carbamazepine controlled-release matrix tablets.
    Ikinci G; Capan Y; Senel S; Dalkara T; Hincal AA
    Pharmazie; 1999 Feb; 54(2):139-41. PubMed ID: 10084159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbamazepine and its epoxide: an open study of efficacy and side effects after carbamazepine dose increment in refractory partial epilepsy.
    Semah F; Gimenez F; Longer E; Laplane D; Thuillier A; Baulac M
    Ther Drug Monit; 1994 Dec; 16(6):537-40. PubMed ID: 7878690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmaceutical and biopharmaceutical quality of a sustained release carbamazepine preparation: a contribution to quality assurance.
    Grunwald F; Czaja J; Düsing R; Schulz HU
    Int J Clin Pharmacol Ther Toxicol; 1992 May; 30(5):160-6. PubMed ID: 1592543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse event load in bipolar participants receiving either carbamazepine immediate-release or extended-release capsules: a blinded, randomized study.
    El-Mallakh RS; Salem MR; Chopra AS; Mickus GJ; Penagaluri P
    Int Clin Psychopharmacol; 2009 May; 24(3):145-9. PubMed ID: 19367153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacology of chewable versus regular carbamazepine in chronically treated children with epilepsy.
    Camfield P; Hwang P; Camfield C; Fraser A; Soldin S; al-Quadah AK
    Can J Neurol Sci; 1992 May; 19(2):204-7. PubMed ID: 1623447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigations into the relative bioavailability of carbamazepine after single oral administration of three test batches of a carbamazepine-containing sustained release formulation in healthy subjects.
    Schulz HU; Düsing R; Grunwald F; Czaja J; Lührmann B; Frecks HJ
    Int J Clin Pharmacol Ther Toxicol; 1992 Apr; 30(4):139-44. PubMed ID: 1572759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.